Search

Your search keyword '"Colavita F"' showing total 173 results
Start Over Author "Colavita F"
173 results on '"Colavita F"'

1. EBOLA Ag K-SeT rapid test: field evaluation in Sierra Leone

Author

Colavita, F., Biava, M., Mertens, P., Gilleman, Q., Borlon, C., Delli Guanti, M., Petrocelli, A., Cataldi, G., Kamara, A.T., Kamara, S.A., Konneh, K., Vincenti, D., Castilletti, C., Abdurahman, S., Mirazimi, A., Capobianchi, M.R., Ippolito, G., Miccio, R., and Di Caro, A.

Published
2018
Full Text
View/download PDF

2. Evaluation of a rapid and sensitive RT-qPCR assay for the detection of Ebola Virus

Author

Biava, M., Colavita, F., Marzorati, A., Russo, D., Pirola, D., Cocci, A., Petrocelli, A., Delli Guanti, M., Cataldi, G., Kamara, T.A., Kamara, A.S., Konneh, K., Cannas, A., Coen, S., Quartu, S., Meschi, S., Valli, M.B., Mazzarelli, A., Venditti, C., Grassi, G., Rozera, G., Castilletti, C., Mirazimi, A., Capobianchi, M.R., Ippolito, G., Miccio, R., and Di Caro, A.

Published
2018
Full Text
View/download PDF

3. In vivo virological efficacy of monoclonal antibodies and direct antiviral agents against the SARS-CoV-2 BA.1 and BA.2 Omicron sublineages

Author

Mazzotta, V, primary, Cozzi Lepri, A, additional, Colavita, F, additional, Rosati, S, additional, Lalle, E, additional, Cimaglia, C, additional, Paulicelli, J, additional, Mastrorosa, I, additional, Vergori, A, additional, Girardi, E, additional, Garbuglia, AR, additional, Vaia, F, additional, Nicastri, E, additional, and Antinori, A, additional

Published
2022
Full Text
View/download PDF

4. Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals

Author

Lapa, D, primary, Grousova, DM, additional, Matusali, G, additional, Meschi, S, additional, Colavita, F, additional, Bettini, A, additional, Gramigna, G, additional, Francalancia, M, additional, Garbuglia, AR, additional, Girardi, E, additional, Puro, V, additional, Antinori, A, additional, Kovyrshina, AV, additional, Dolzhikova, IV, additional, Shcheblyakov, DV, additional, Tukhvatulin, AI, additional, Zubkova, OV, additional, Logunov, DY, additional, Naroditsky, BS, additional, Vaia, F, additional, and Gintsburg, AL, additional

Published
2022
Full Text
View/download PDF

5. Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia

Author

Vergori, A., Lorenzini, P., Cozzi-Lepri, A., Donno, D. R., Gualano, G., Nicastri, E., Iacomi, F., Marchioni, L., Campioni, P., Schinina, V., Cicalini, S., Agrati, C., Capobianchi, M. R., Girardi, E., Ippolito, G., Vaia, F., Petrosillo, N., Antinori, A., Taglietti, F., The ReCOVeRI Study Group: Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Castilletti, C., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Corpolongo, A., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., D'Offizi, G., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Fusto, M., Galati, V., Gagliardini, R., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Iaconi, M., Iannicelli, G., Inversi, C., Lalle, E., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Loiacono, L., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Mondi, A., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palmieri, F., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Valli, M. B., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., Zanetti, A., Zito, S., Vergori, A., Lorenzini, P., Cozzi-Lepri, A., Donno, D. R., Gualano, G., Nicastri, E., Iacomi, F., Marchioni, L., Campioni, P., Schinina, V., Cicalini, S., Agrati, C., Capobianchi, M. R., Girardi, E., Ippolito, G., Vaia, F., Petrosillo, N., Antinori, A., Taglietti, F., Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Castilletti, C., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Corpolongo, A., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., D'Offizi, G., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Fusto, M., Galati, V., Gagliardini, R., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Iaconi, M., Iannicelli, G., Inversi, C., Lalle, E., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Loiacono, L., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Mondi, A., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palmieri, F., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Valli, M. B., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., Zanetti, A., and Zito, S.

Subjects
Male, medicine.medical_treatment, Rome, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, Severity of Illness Index, 0302 clinical medicine, Retrospective Studie, Coagulopathy, Clinical endpoint, Intubation, Respiratory function, 030212 general & internal medicine, Multidisciplinary, Middle Aged, Medicine, Female, Human, medicine.medical_specialty, Patients, medicine.drug_class, Science, Low molecular weight heparin, Risk Assessment, Article, NO, 03 medical and health sciences, Internal medicine, Severity of illness, medicine, Intubation, Intratracheal, Humans, Retrospective Studies, Aged, business.industry, SARS-CoV-2, COVID-19, Thrombocytopenia, Retrospective cohort study, Heparin, Low-Molecular-Weight, medicine.disease, Respiration, Artificial, COVID-19 Drug Treatment, respiratory tract diseases, Pneumonia, Viral infection, business
Abstract

Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The aim of this study was to evaluate whether the antinflammatory effects of pLMWH could translate in lower rate of clinical progression in patients with COVID-19 pneumonia. Patients admitted to a COVID-hospital in Rome with SARS-CoV-2 infection and mild/moderate pneumonia were retrospectively evaluated. The primary endpoint was the time from hospital admission to orotracheal intubation/death (OTI/death). A total of 449 patients were included: 39% female, median age 63 (IQR, 50–77) years. The estimated probability of OTI/death for patients receiving pLMWH was: 9.5% (95% CI 3.2–26.4) by day 20 in those not receiving pLMWH vs. 10.4% (6.7–15.9) in those exposed to pLMWH; p-value = 0.144. This risk associated with the use of pLMWH appeared to vary by PaO2/FiO2 ratio: aHR 1.40 (95% CI 0.51–3.79) for patients with an admission PaO2/FiO2 ≤ 300 mmHg and 0.27 (0.03–2.18) for those with PaO2/FiO2 > 300 mmHg; p-value at interaction test 0.16. pLMWH does not seem to reduce the risk of OTI/death mild/moderate COVID-19 pneumonia, especially when respiratory function had already significantly deteriorated. Data from clinical trials comparing the effect of prophylactic vs. therapeutic dosage of LMWH at various stages of COVID-19 disease are needed.

Published
2021

6. SARS-CoV-2 isolation from ocular secretions of a patient with COVID-19 in Italy with prolonged viral RNA detection

Author

Colavita F., Lapa D., Carletti F., Lalle E., Bordi L., Marsella P., Nicastri E., Bevilacqua N., Giancola M. L., Corpolongo A., Ippolito G., Capobianchi M. R., Castilletti C., Abbonizio M. A., Agrati C., Albarello F., Amadei G., Amendola A., Antonini M., Barbaro R., Bartolini B., Benigni M., Bordoni V., Branca M., Campioni P., Caporale C., Caravella I., Chiappini R., Ciaralli C., Cristofaro M., Curiale S., D'Abramo A., Dantimi C., de Angelis A., de Angelis G., Di Lorenzo R., Di Stefano F., Ferraro F., Fiorentini L., Frustaci A., Galli P., Garotto G., Giansante F., Giombini E., Greci M. C., Lanini S., Lepore L., Lucia A., Lufrani F., Macchione M., Marani A., Marchioni L., Mariano A., Marini M. C., Maritti M., Matusali G., Meschi S., Messina F., Montaldo C., Murachelli S., Noto R., Palazzolo C., Pallini E., Passeri V., Pelliccioni F., Petrecchia A., Petrone A., Petrosillo N., Pianura E., Pisciotta M., Pittalis S., Proietti C., Puro V., Rinonapoli G., Rueca M., Sacchi A., Sanasi F., Santagata C., Scarcia S., Schinina V., Scognamiglio P., Scorzolini L., Stazi G., Vaia F., Vairo F., Valli M. B., Colavita, F., Lapa, D., Carletti, F., Lalle, E., Bordi, L., Marsella, P., Nicastri, E., Bevilacqua, N., Giancola, M. L., Corpolongo, A., Ippolito, G., Capobianchi, M. R., Castilletti, C., Abbonizio, M. A., Agrati, C., Albarello, F., Amadei, G., Amendola, A., Antonini, M., Barbaro, R., Bartolini, B., Benigni, M., Bordoni, V., Branca, M., Campioni, P., Caporale, C., Caravella, I., Chiappini, R., Ciaralli, C., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., de Angelis, A., de Angelis, G., Di Lorenzo, R., Di Stefano, F., Ferraro, F., Fiorentini, L., Frustaci, A., Galli, P., Garotto, G., Giansante, F., Giombini, E., Greci, M. C., Lanini, S., Lepore, L., Lucia, A., Lufrani, F., Macchione, M., Marani, A., Marchioni, L., Mariano, A., Marini, M. C., Maritti, M., Matusali, G., Meschi, S., Messina, F., Montaldo, C., Murachelli, S., Noto, R., Palazzolo, C., Pallini, E., Passeri, V., Pelliccioni, F., Petrecchia, A., Petrone, A., Petrosillo, N., Pianura, E., Pisciotta, M., Pittalis, S., Proietti, C., Puro, V., Rinonapoli, G., Rueca, M., Sacchi, A., Sanasi, F., Santagata, C., Scarcia, S., Schinina, V., Scognamiglio, P., Scorzolini, L., Stazi, G., Vaia, F., Vairo, F., and Valli, M. B.

Subjects
Isolation (health care), Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Eye, NO, 03 medical and health sciences, 0302 clinical medicine, Internal Medicine, Medicine, Viral rna, 030304 developmental biology, 0303 health sciences, SARS-CoV-2, business.industry, COVID-19, RNA, Pneumonia, General Medicine, Conjunctivitis, medicine.disease, Letters: Observations, Virology, 3. Good health, Viral replication, 030221 ophthalmology & optometry, business, Viral load, COVID-19, Conjunctivitis, Eye, Pneumonia, SARS-CoV-2
Abstract

Background: Coronavirus disease 2019 (COVID-19), the disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that originated in China in December 2019, was recently recognized as pandemic threat by the World Health Organization, with the potential of rapidly overloading health care systems and causing substantial mortality worldwide (www.who.int/dg/speeches/detail/who-director-general -s-opening-remarks-at-the-media-briefing-on-covid-19 —11-march -2020). Human-to-human transmission occurs mainly through respiratory droplets, but other routes are under investigation, because SARS-CoV-2 has been detected in several body fluids (1). So far, few data are available on ocular samples from patients with COVID-19, although conjunctivitis has been occasionally reported among COVID-19 symptoms, similar to infections caused by other human coronaviruses (2, 3). During the SARS epidemic, eye exposure to infectious fluids was associated with an increased risk for SARS-CoV transmission to health care workers (3, 4). Although SARS-CoV RNA was occasionally found in ocular specimens during the early phase of illness, its infectivity is unknown (2, 3). With regard to COVID-19, unprotected ocular exposure was thought to be responsible for infections that occurred in the Wuhan Fever Clinic in January 2020 (3, 4); in addition, SARS-CoV-2 RNA was detected in conjunctival secretions collected from the only patient with conjunctivitis out of 30 patients with COVID-19 from a hospital in China (5). However, further studies are needed to evaluate the infectious potential of the SARS-CoV-2 RNA detected in the ocular specimens and to determine whether transmission may occur through ocular secretions (3, 4). Objective: To present the early detection of infectious SARS-CoV-2 in ocular fluids from a patient with the first confirmed case of COVID-19 in Italy, who had been hospitalized at the National Institute for Infectious Diseases “L. Spallanzani” (INMI) in Rome. Methods and Findings: The patient, a 65-year-old woman, travelled from Wuhan, China, to Italy on 23 January 2020 and was admitted on 29 January 2020, 1 day after symptom onset. At admission to the high isolation unit at INMI, she presented with nonproductive cough, sore throat, coryza, and bilateral conjunctivitis. She had no fever until day 4, when fever (38 °C), nausea, and vomiting began. Infection with SARS-CoV-2 was confirmed by performing real-time reverse transcription polymerase chain reaction (RT-PCR) assay on sputum samples (cycle threshold value [Ct], 16.1) on the admission day, followed by viral M gene sequencing (GenBank accession number MT008022), and virus isolation on Vero E6 cell line (2019-nCoV/Italy-INMI1). The full genome sequence was obtained from either clinical sample or culture isolate (GISAID accession numbers EPI_ISL_410545 and EPI_ISL_410546). At admission, no other respiratory infections were detected (QIAstat-Dx Respiratory Panel; Qiagen).

Published
2020

8. Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

Author

Conforti A, Marra E, Palombo F, Roscilli G, Ravà M, Fumagalli V, Muzi A, Maffei M, Luberto L, Lione L, Salvatori E, Compagnone M, Pinto E, Pavoni E, Bucci F, Vitagliano G, Stoppoloni D, Pacello ML, Cappelletti M, Ferrara FF, D'Acunto E, Chiarini V, Arriga R, Nyska A, Di Lucia P, Marotta D, Bono E, Giustini L, Sala E, Perucchini C, Paterson J, Ryan KA, Challis AR, Matusali G, Colavita F, Caselli G

Published
2021
Full Text
View/download PDF

12. Advances in technology for high-energy subnuclear physics Contribution of the LAA project

Author

Acosta, D., Alberty, J., Alsford, J., Alvisi, C., Ambrosi, G., Anghinolfi, F., Anselmo, F., Anzivino, G., Arneodo, M., Arnold, R., Arzarello, F., Aspell, P., Barberio, L. E., Bari, G., Barillari, T., Basile, M., Battiston, R., Baudoin-Bijst, C., Becker, U., Bellagamba, L., Bénot, M., Benvenuto, P., Berbiers, J., Berdugo, J., Bergsma, F., Bertin, R., Bingefors, N., Bisello, D., Bock, R. K., Boscherini, D., Bosteels, M., Bouclier, R., Bramhall, M., Bruni, G., Buontempo, S., Calôba, L., Campbell, M., Caputi, L., Romeo, G. Cara, Caria, M., Casaccia, R., Castro, H., Ceresara, S., Chapuis, J. M., Charpak, G., Chesi, E., Chiarini, M., Christiansen, J., Christofel, E., Cifarelli, L., Cindolo, F., Colavita, F., Coninckx, F., Contin, A., Costa, M., Crotty, I., D’Alí, G., D’Ambrosio, C., D’Auria, S., Dardo, M., Del Papa, C., Della Gatta, G., De Pasquale, S., De Salvo, R., De Seixas, J. M., Destruel, P., de Witt, J., Di Rosa, O., Dorfan, D., Duchovni, E., Dupont, J., Dupraz, J., Egger, J., Ekelof, T., Enz, C. C., Ereditato, A., Ermoline, Y., Fabre, J. P., Feraudet, P., Ferrari, R., Fiori, F., Ford, P., Frasconi, F., Fraternali, M., French, M., Fuchs, M., Fumagalli, G., Gabathuler, K., Galvez, J., Gaudaen, J., Gildemeister, O., Giomataris, Y., Girod, J. P., Giusti, P., Goebel, K., Goiugas, A., Grinnel, C., Güsten, H., Guyonnet, J. L., Gys, T., Hartjes, F., Hazifotiadu, D., Heijne, E., Henkes, T., Henriques, A. M., Hourican, M., Iacobucci, G., Iuvino, G., Jarron, P., Jenni, P., Jobez, J. P., Joram, C., Kluge, W., Krisher, W., Krummenacher, F., Kuzucu, A., Laakso, I., Labbe, J. C., La Commare, G., Larsen, H., Laurenti, G., Lee, T. D., Letheren, M., Leutz, H., Levi, G., Levinson, L., Lin, Q., Linssen, L., Lisowski, B., Litke, A., Livan, M., Ljuslin, C., Lone, L., Maccarrone, G., Maio, A., Mapelli, L., Marchioro, A., Margotti, A., Marino, M., Massam, T., Matsuda, T., Matsuura, T., Mattern, D., Meddeler, G., Meier, K. H., Meng, R., Mikenberg, G., Million, G., Mondardini, M. R., Mörk, G., Morpurgo, M., Musso, B., Nania, R., Nemoz, C., Newett, S., Oliva, A., Olsen, A., Ong, B., O’Shea, V., Ozdes, N., Paar, H. P., Palermo, L., Cernicchiaro, S. Palermo, Palmonari, F., Passardi, G., Pastore, F., Pelfer, P., Pereira, M., Peroni, C., Perotto, E., Peskov, V., Piedigrossi, D., Pilastrini, R., Pitzl, D., Poggioli, L., Pol, M. E., Qian, S., Racz, A., Rivera, F., Rose-Dulcina, L., Ruf, T., Sadrozinski, H., Salgne, R., Sandoval, A., Sannier, G., Santiard, J. C., Sartorelli, G., Sartori, P., Sauli, F., Scheel, C., Schioppa, M., Schipper, J., Schönbacher, H., Scigocki, D., Scioni, M., Seguinot, J., Seiden, A., Seidl, W., Seixas, J. M., Sharp, P., Sigrist, A., Simon, A., Simonet, G., Sivertz, M., Smith, K., Sonderegger, P., Souza, M. N., Spencer, E., Sportelli, L., Staiano, K., Susinno, G. C., Tailhardat, S., Taufer, M., Taufer, M., Tavlet, M., Terraneo, A. E., Thomé, Z. D., Timellini, R., Tischhauser, J., Tocqueville, J., Valencic, V., Van Eijk, B., Vanstraelen, G., Vercesi, V., Votano, L., Wenninger, H., Werner, C., Wigmans, R., Williams, C., Ypsilantis, G., Zaganidis, N., Zichichi, A., and Zografos, K.

Published
1990
Full Text
View/download PDF

15. Overproduction of IL-6 and Type I IFN in a lethal case of Chikungunya virus infection in an elderly man during the 2017 Italian outbreak

Author

Colavita, F., primary, Vita, S., additional, Lalle, E., additional, Bordi, L., additional, Carletti, F., additional, Pozzetto, I., additional, Aiuti, M., additional, Vincenti, D., additional, Cimini, E., additional, Vairo, F., additional, Capobianchi, M.R., additional, Lichtner, M., additional, and Castilletti, C., additional

Published
2019
Full Text
View/download PDF

17. Detection of viral RNA in tissues following plasma clearance from an Ebola virus infected patient

Author

Biava, M., primary, Caglioti, C., additional, Bordi, L., additional, Castilletti, C., additional, Colavita, F., additional, Quartu, S., additional, Nicastri, E., additional, Lauria, F.N., additional, Petrosillo, N., additional, Lanini, S., additional, Hoenen, T., additional, Kobinger, G., additional, Zumla, A., additional, Di Caro, A., additional, Ippolito, G., additional, Capobianchi, M.R., additional, and Lalle, E., additional

Published
2016
Full Text
View/download PDF

18. Molecular signature of the Ebola virus associated with the fishermen community outbreak in Aberdeen, Sierra Leone, in February 2015

Author

Capobianchi, M, Gruber, C, Carletti, F, Meschi, S, Castilletti, C, Vairo, F, Biava, M, Minosse, C, Strada, G, Portella, G, Miccio, R, Minardi, V, Rolla, L, Kamara, A, Chillemi, G, Desideri, A, Di Caro, A, Ippolito, G, Cannas, A, Venditti, C, Zaccaro, P, Colavita, F, Mazzarelli, A, Vulcano, A, Chiappini, R, Valli, M, Grassi, G, Lapa, D, Quartu, S, and Coen, S

Subjects
Ebola virus, Settore BIO/11, Outbreak, Subclade, Biology, Disease cluster, Bioinformatics, medicine.disease_cause, Virology, 3. Good health, Sierra leone, Viruses, Genetics, medicine, Molecular Biology, Health worker
Abstract

We report the complete genome sequence of Ebola virus from a health worker linked to a cluster of cases occurring in the fishing community of Aberdeen, Sierra Leone (February 2015), which were characterized by unusually severe presentation. The sequence, clustering in the SL subclade 3.2.4, harbors mutations potentially relevant for pathogenesis.

Published
2015

24. First Italian Ebola virus disease case: Management of hospital internal and external communication

Author

Salce, L., Barbato, S., Renna, D., Bianchini, F., Vaccaro, P., Mazzeo, F., Gasparini, A., Rizza, C., Lanfranchi, E., Petrosillo, N., Nicastri, E., Di Caro, A., Capobianchi, M. R., vincenzo puro, Ippolito, G., Bevilacqua, N., Boumis, E., Cicalini, S., Chinello, P., Corpolongo, A., Galati, V., Mariano, A., Rosati, S., Taglietti, F., Vincenzi, L., Antonini, M., Caravella, I., Garotto, G., Marchioni, L., Maritti, M., Biava, G., Rizzi, E. B., Castilletti, C., Bordi, L., Lalle, E., Meschi, S., Lapa, D., Marsella, P., Colavita, F., Chiappini, R., Mazzarelli, A., Quartu, S., Agrati, C., Carletti, F., Forbici, F., Valli, M. B., Abbate, I., Amendola, A., Garbuglia, A. R., Paglia, M. G., Bordi, E., Travaglini, D., Toffoletti, A., Battisti, G., Coppola, A., Marchis, L., Marco, N., Giacomini, P., Di Gianbattista, F., Guiducci, M., Marasco, A., Marzolini, A., Mercuri, A., Nieddu, P., Ondedei, S., Vescovo, M., Vitolo, L., Morea, M., Liguori, M., Lauria, F. N., Russo, A., D Aprile, P., Petrecchia, A., Gentile, M., Pittalis, S., Martini, L., Fusco, F. M., Lanini, S., Antinori, A., and Alberti, V. F.

27. SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus

Author

Matusali G., Colavita F., Lapa D., Meschi S., Bordi L., Piselli P., Gagliardini R., Corpolongo A., Nicastri E., Antinori A., Ippolito G., Capobianchi M. R., Castilletti C., Abbate I., Agrati C., Aleo L., Alonzi T., Amendola A., Apollonio C., Arduini N., Bartolini B., Berno G., Biancone S., Bibbo A., Brega C., Canali M., Cannas A., Carletti F., Carrara S., Casetti R., Castillettiy C., Chiappini R., Ciafrone L., Cimini E., Coen S., Condello R., Coppola A., D'arezzo S., Di Caro A., Di Filippo S., De Giuli C., Fabeni L., Felici L., Ferraioli V., Forbici F., Garbuglia A. R., Giombini E., Gruber C. E. M., Khouri D., Lalle E., Leone B., Mazzarelli A., Messina F., Minosse C., Montaldo C., Neri S., Nisii C., Petrivelli E., Petroni F., Petruccioli E., Pisciotta M., Pizzi D., Prota G., Rozera G., Rueca M., Sabatini R., Sarti S., Sberna G., Sciamanna R., Selleri M., Selvaggi C., Stellitano C., Toffoletti A., Truffa S., Turchi F., Valli M. B., Venditti C., Vincenti D., Vulcano A., Zambelli E., Bevilacqua N., Bordoni V., D'abramo A., Lepore L., Mariano A., Palazzolo C., Lorenzini P., Notari S., Sacchi A., Scorzolini L., Bettini A., Francalancia M., Specchiarello E., Federica M., Gaetano D., Luigi F., Barbara G., Roberto I., Giovanni M., Mirco M., Rachele S., Matusali, G., Colavita, F., Lapa, D., Meschi, S., Bordi, L., Piselli, P., Gagliardini, R., Corpolongo, A., Nicastri, E., Antinori, A., Ippolito, G., Capobianchi, M. R., Castilletti, C., Abbate, I., Agrati, C., Aleo, L., Alonzi, T., Amendola, A., Apollonio, C., Arduini, N., Bartolini, B., Berno, G., Biancone, S., Bibbo, A., Brega, C., Canali, M., Cannas, A., Carletti, F., Carrara, S., Casetti, R., Castillettiy, C., Chiappini, R., Ciafrone, L., Cimini, E., Coen, S., Condello, R., Coppola, A., D'Arezzo, S., Di Caro, A., Di Filippo, S., De Giuli, C., Fabeni, L., Felici, L., Ferraioli, V., Forbici, F., Garbuglia, A. R., Giombini, E., Gruber, C. E. M., Khouri, D., Lalle, E., Leone, B., Mazzarelli, A., Messina, F., Minosse, C., Montaldo, C., Neri, S., Nisii, C., Petrivelli, E., Petroni, F., Petruccioli, E., Pisciotta, M., Pizzi, D., Prota, G., Rozera, G., Rueca, M., Sabatini, R., Sarti, S., Sberna, G., Sciamanna, R., Selleri, M., Selvaggi, C., Stellitano, C., Toffoletti, A., Truffa, S., Turchi, F., Valli, M. B., Venditti, C., Vincenti, D., Vulcano, A., Zambelli, E., Bevilacqua, N., Bordoni, V., D'Abramo, A., Lepore, L., Mariano, A., Palazzolo, C., Lorenzini, P., Notari, S., Sacchi, A., Scorzolini, L., Bettini, A., Francalancia, M., Specchiarello, E., Federica, M., Gaetano, D., Luigi, F., Barbara, G., Roberto, I., Giovanni, M., Mirco, M., and Rachele, S.

Subjects
0301 basic medicine, Male, lcsh:QR1-502, serology, Antibodies, Viral, lcsh:Microbiology, Serology, protective immunity, 0302 clinical medicine, Medicine, 030212 general & internal medicine, Neutralizing antibody, biology, Middle Aged, 3. Good health, Algorithm, Titer, Infectious Diseases, Female, Neutralization Test, Algorithms, Human, Adult, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Protective immunity, Article, Virus, COVID-19 Serological Testing, 03 medical and health sciences, Neutralization Tests, Immunity, Virology, Neutralizing antibodie, Humans, neutralizing antibodies, Kinetic, Receiver operating characteristic, business.industry, SARS-CoV-2, COVID-19, Gold standard (test), Antibodies, Neutralizing, Kinetics, 030104 developmental biology, ROC Curve, Immunoglobulin G, Immunology, biology.protein, business
Abstract

SARS-CoV-2 serum neutralization assay represents the gold standard for assessing antibody-mediated protection in naturally infected and vaccinated individuals. In the present study, 662 serum samples collected from February 2020 to January 2021 from acute and convalescent COVID-19 patients were tested to determine neutralizing antibody (NAb) titers using a microneutralization test (MNT) for live SARS-CoV-2. Moreover, anti-SARS-CoV-2 IgG, IgA, and IgM directed against different viral antigens were measured by high-throughput automated platforms. We observed higher levels of NAbs in elderly (&gt, 60 years old) individuals and in patients presenting acute respiratory distress syndrome. SARS-CoV-2 NAbs develop as soon as five days from symptom onset and, despite a decline after the second month, persist for over 11 months, showing variable dynamics. Through correlation and receiver operating characteristic (ROC) curve analysis, we set up a testing algorithm, suitable for the laboratory workload, by establishing an optimal cutoff value of anti-SARS-CoV-2 IgG for convalescent plasma donors to exclude from MNT samples foreseen to have low/negative NAb titers and ineligible for plasma donation. Overall, MNT, although cumbersome and not suitable for routine testing of large sample sizes, remains the reference tool for the assessment of antibody-mediated immunity after SARS-CoV-2 infection. Smart testing algorithms may optimize the laboratory workflow to monitor antibody-mediated protection in COVID-19 patients, plasma donors, and vaccinated individuals.

Full Text
View/download PDF

28. Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome

Author

Serena Vita, Virginia Di Bari, Angela Corpolongo, Delia Goletti, Joaquin Espinosa, Sebastiano Petracca, Fabrizio Palmieri, Emanuele Nicastri, null Abbonizio, Chiara Agrati, Fabrizio Albarello, Gioia Amadei, Alessandra Amendola, Mario Antonini, Raffaella Barbaro, Barbara Bartolini, Martina Benigni, Nazario Bevilacqua, Licia Bordi, Veronica Bordoni, Marta Branca, Paolo Campioni, Maria Rosaria Capobianchi, Cinzia Caporale, Ilaria Caravella, Fabrizio Carletti, Concetta Castilletti, Roberta Chiappini, Carmine Ciaralli, Francesca Colavita, Massimo Cristofaro, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Rachele Di Lorenzo, Federica Di Stefano, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Paola Gallì, Gabriele Garotto, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Maria Cristina Greci, Giuseppe Ippolito, Eleonora Lalle, Simone Lanini, Daniele Lapa, Luciana Lepore, Andrea Lucia, Franco Lufrani, Manuela Macchione, Alessandra Marani, Luisa Marchioni, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Giulia Matusali, Silvia Meschi, Francesco Messina Chiara Montaldo, Silvia Murachelli, Roberto Noto, Claudia Palazzolo, Emanuele Pallini, Virgilio Passeri, Federico Pelliccioni, Antonella Petrecchia, Ada Petrone, Nicola Petrosillo, Elisa Pianura, Maria Pisciotta, Silvia Pittalis, Costanza Proietti, Vincenzo Puro, Gabriele Rinonapoli, Martina Rueca, Alessandra Sacchi, Francesco Sanasi, Carmen Santagata, Silvana Scarcia, Vincenzo Schininà, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Francesco Vaia, Francesco Vairo, Maria Beatrice Valli, Vita, S., Di Bari, V., Corpolongo, A., Goletti, D., Espinosa, J., Petracca, S., Palmieri, F., Nicastri, E., Abbonizio, Agrati, C., Albarello, F., Amadei, G., Amendola, A., Antonini, M., Barbaro, R., Bartolini, B., Benigni, M., Bevilacqua, N., Bordi, L., Bordoni, V., Branca, M., Campioni, P., Capobianchi, M. R., Caporale, C., Caravella, I., Carletti, F., Castilletti, C., Chiappini, R., Ciaralli, C., Colavita, F., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., Angelis, A. D., Angelis, G. D., Lorenzo, R. D., Stefano, F. D., Ferraro, F., Fiorentini, L., Frustaci, A., Galli, P., Garotto, G., Giancola, M. L., Giansante, F., Giombini, E., Greci, M. C., Ippolito, G., Lalle, E., Lanini, S., Lapa, D., Lepore, L., Lucia, A., Lufrani, F., Macchione, M., Marani, A., Marchioni, L., Mariano, A., Marini, M. C., Maritti, M., Matusali, G., Meschi, S., Montaldo, F. M. C., Murachelli, S., Noto, R., Palazzolo, C., Pallini, E., Passeri, V., Pelliccioni, F., Petrecchia, A., Petrone, A., Petrosillo, N., Pianura, E., Pisciotta, M., Pittalis, S., Proietti, C., Puro, V., Rinonapoli, G., Rueca, M., Sacchi, A., Sanasi, F., Santagata, C., Scarcia, S., Schinina, V., Scognamiglio, P., Scorzolini, L., Stazi, G., Vaia, F., Vairo, F., and Valli, M. B.

Subjects
0301 basic medicine, Microbiology (medical), Pediatrics, medicine.medical_specialty, Down syndrome, immuneactivation, 030106 microbiology, Case Report, medicine.disease_cause, NO, lcsh:Infectious and parasitic diseases, 03 medical and health sciences, 0302 clinical medicine, medicine, Clinical significance, lcsh:RC109-216, 030212 general & internal medicine, COVID-19 pneumonia, ComputingMethodologies_COMPUTERGRAPHICS, Coronavirus, Immune activation, business.industry, General Medicine, Immune dysregulation, medicine.disease, Vaccination, Pneumonia, Infectious Diseases, medicine.anatomical_structure, business, Trisomy, Respiratory tract
Abstract

Graphical abstract, Highlights • Pro-inflammatory factors play a central role in COVID-19 severity and mortality. • Down Syndrome is characterized by immune dysregulation and respiratory infections. • Down Syndrome patients with COVID-19 are at high-risk for unfavourable outcome., We report two cases of COronaVIrus Disease-19 in patients with Down Syndrome and describe the identification, diagnosis, clinical course, and management of the infection. Down Syndrome, which is caused by trisomy 21, is characterized by immune dysregulation, anatomical differences in the upper respiratory tract, and higher rate of comorbidities. All these risk factors can contribute to more severe clinical presentations of COVID-19. It is essential to raise awareness of the clinical relevance of SARS-COV-2 infection in DS patients, as well in other most vulnerable patients in order to improve their management and treatment and to candidate these individuals for vaccination, once available.

Published
2021

29. 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation

Author

Fabrizio Albarello, Elisa Pianura, Federica Di Stefano, Massimo Cristofaro, Ada Petrone, Luisa Marchioni, Claudia Palazzolo, Vincenzo Schininà, Emanuele Nicastri, Nicola Petrosillo, Paolo Campioni, Petersen Eskild, Alimuddin Zumla, Giuseppe Ippolito, Maria Alessandra Abbonizio, Chiara Agrati, Gioia Amadei, Alessandra Amendola, Mario Antonini, Raffaella Barbaro, Barbara Bartolini, Martina Benigni, Nazario Bevilacqua, Licia Bordi, Veronica Bordoni, Marta Branca, Maria Rosaria Capobianchi, Cinzia Caporale, Ilaria Caravella, Fabrizio Carletti, Concetta Castilletti, Roberta Chiappini, Carmine Ciaralli, Francesca Colavita, Angela Corpolongo, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Rachele Di Lorenzo, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Paola Gallì, Gabriele Garotto, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Maria Cristina Greci, Eleonora Lalle, Simone Lanini, Daniele Lapa, Luciana Lepore, Andrea Lucia, Franco Lufrani, Manuela Macchione, Alessandra Marani, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Giulia Matusali, Silvia Meschi, Francesco Messina Chiara Montaldo, Silvia Murachelli, Roberto Noto, Emanuele Pallini, Virgilio Passeri, Federico Pelliccioni, Antonella Petrecchia, Maria Pisciotta, Silvia Pittalis, Costanza Proietti, Vincenzo Puro, Gabriele Rinonapoli, Martina Rueca, Alessandra Sacchi, Francesco Sanasi, Carmen Santagata, Silvana Scarcia, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Francesco Vaia, Francesco Vairo, Maria Beatrice Valli, Albarello, F., Pianura, E., Di Stefano, F., Cristofaro, M., Petrone, A., Marchioni, L., Palazzolo, C., Schinina, V., Nicastri, E., Petrosillo, N., Campioni, P., Eskild, P., Zumla, A., Ippolito, G., Abbonizio, M. A., Agrati, C., Amadei, G., Amendola, A., Antonini, M., Barbaro, R., Bartolini, B., Benigni, M., Bevilacqua, N., Bordi, L., Bordoni, V., Branca, M., Capobianchi, M. R., Caporale, C., Caravella, I., Carletti, F., Castilletti, C., Chiappini, R., Ciaralli, C., Colavita, F., Corpolongo, A., Curiale, S., D'Abramo, A., Dantimi, C., Angelis, A. D., Angelis, G. D., Lorenzo, R. D., Stefano, F. D., Ferraro, F., Fiorentini, L., Frustaci, A., Galli, P., Garotto, G., Giancola, M. L., Giansante, F., Giombini, E., Greci, M. C., Lalle, E., Lanini, S., Lapa, D., Lepore, L., Lucia, A., Lufrani, F., Macchione, M., Marani, A., Mariano, A., Marini, M. C., Maritti, M., Matusali, G., Meschi, S., Montaldo, F. M. C., Murachelli, S., Noto, R., Pallini, E., Passeri, V., Pelliccioni, F., Petrecchia, A., Pisciotta, M., Pittalis, S., Proietti, C., Puro, V., Rinonapoli, G., Rueca, M., Sacchi, A., Sanasi, F., Santagata, C., Scarcia, S., Scognamiglio, P., Scorzolini, L., Stazi, G., Vaia, F., Vairo, F., and Valli, M. B.

Subjects
0301 basic medicine, ARDS, medicine.disease_cause, 0302 clinical medicine, SARS-COV2, 030212 general & internal medicine, Lung, Respiratory Distress Syndrome, Respiratory distress, Ground glass opacitie, General Medicine, Crazy-paving, Infectious Diseases, medicine.anatomical_structure, Italy, Severe acute respiratory syndrome-related coronavirus, Radiological weapon, Disease Progression, Middle East Respiratory Syndrome Coronavirus, Radiology, medicine.symptom, Presentation (obstetrics), Coronavirus Infections, Ground glass opacities, Adult, Microbiology (medical), China, medicine.medical_specialty, Mediastinal lymphadenopathy, Middle East respiratory syndrome coronavirus, Pneumonia, Viral, 030106 microbiology, Article, NO, lcsh:Infectious and parasitic diseases, Lesion, Betacoronavirus, 03 medical and health sciences, medicine, Humans, LS7_2, lcsh:RC109-216, Pandemics, Enlarged pulmonary vessel, SARS-CoV-2, business.industry, COVID-19, CT-scan, Enlarged pulmonary vessels, medicine.disease, Tomography, X-Ray Computed, business
Abstract

Highlights • The first two patients identified in Italy with COVID-19 presented remarkable imaging findings who progressed in adult respiratory distress syndrome. • Uncommon elements such as pleural effusions, a tubular and enlarged appearance of pulmonary vessels with a sudden caliber reduction and mediastinal lymphadenopathy were noted during the follow-up. • The vessels appearance during the follow up, resembling a “feeding vessel sign”, could be an early alert radiological sign to predict initial lung deterioration., Introduction Several recent case reports have described common early chest imaging findings of lung pathology caused by 2019 novel Coronavirus (SARS-COV2) which appear to be similar to those seen previously in SARS-CoV and MERS-CoV infected patients. Objective We present some remarkable imaging findings of the first two patients identified in Italy with COVID-19 infection travelling from Wuhan, China. The follow-up with chest X-Rays and CT scans was also included, showing a progressive adult respiratory distress syndrome (ARDS). Results Moderate to severe progression of the lung infiltrates, with increasing percentage of high-density infiltrates sustained by a bilateral and multi-segmental extension of lung opacities, were seen. During the follow-up, apart from pleural effusions, a tubular and enlarged appearance of pulmonary vessels with a sudden caliber reduction was seen, mainly found in the dichotomic tracts, where the center of a new insurgent pulmonary lesion was seen. It could be an early alert radiological sign to predict initial lung deterioration. Another uncommon element was the presence of mediastinal lymphadenopathy with short-axis oval nodes. Conclusions Although only two patients have been studied, these findings are consistent with the radiological pattern described in literature. Finally, the pulmonary vessels enlargement in areas where new lung infiltrates develop in the follow-up CT scan, could describe an early predictor radiological sign of lung impairment.

Published
2020

30. Multi-omics approach to COVID-19: a domain-based literature review

Author

Chiara Montaldo, Francesco Messina, Isabella Abbate, Manuela Antonioli, Veronica Bordoni, Alessandra Aiello, Fabiola Ciccosanti, Francesca Colavita, Chiara Farroni, Saeid Najafi Fard, Emanuela Giombini, Delia Goletti, Giulia Matusali, Gabriella Rozera, Martina Rueca, Alessandra Sacchi, Mauro Piacentini, Chiara Agrati, Gian Maria Fimia, Maria Rosaria Capobianchi, Francesco Nicola Lauria, Giuseppe Ippolito, Montaldo, C., Messina, F., Abbate, I., Antonioli, M., Bordoni, V., Aiello, A., Ciccosanti, F., Colavita, F., Farroni, C., Najafi Fard, S., Giombini, E., Goletti, D., Matusali, G., Rozera, G., Rueca, M., Sacchi, A., Piacentini, M., Agrati, C., Fimia, G. M., Capobianchi, M. R., Lauria, F. N., and Ippolito, G.

Subjects
COVID-19, Conceptual domain, Host signatures, Omics, Pathways, Phenotypes, SARS-CoV-2, Settore BIO/06, Pandemic, General Medicine, Review, General Biochemistry, Genetics and Molecular Biology, Immunity, Innate, Phenotype, Host signature, Omic, Medicine, Humans, Pandemics, Pathway, Human
Abstract

Background Omics data, driven by rapid advances in laboratory techniques, have been generated very quickly during the COVID-19 pandemic. Our aim is to use omics data to highlight the involvement of specific pathways, as well as that of cell types and organs, in the pathophysiology of COVID-19, and to highlight their links with clinical phenotypes of SARS-CoV-2 infection. Methods The analysis was based on the domain model, where for domain it is intended a conceptual repository, useful to summarize multiple biological pathways involved at different levels. The relevant domains considered in the analysis were: virus, pathways and phenotypes. An interdisciplinary expert working group was defined for each domain, to carry out an independent literature scoping review. Results The analysis revealed that dysregulated pathways of innate immune responses, (i.e., complement activation, inflammatory responses, neutrophil activation and degranulation, platelet degranulation) can affect COVID-19 progression and outcomes. These results are consistent with several clinical studies. Conclusions Multi-omics approach may help to further investigate unknown aspects of the disease. However, the disease mechanisms are too complex to be explained by a single molecular signature and it is necessary to consider an integrated approach to identify hallmarks of severity.

Published
2021

31. Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine

Author

Chiara Agrati, Concetta Castilletti, Delia Goletti, Silvia Meschi, Alessandra Sacchi, Giulia Matusali, Veronica Bordoni, Linda Petrone, Daniele Lapa, Stefania Notari, Valentina Vanini, Francesca Colavita, Alessandra Aiello, Alessandro Agresta, Chiara Farroni, Germana Grassi, Sara Leone, Francesco Vaia, Maria Rosaria Capobianchi, Giuseppe Ippolito, Vincenzo Puro, on behalf of the INMI COVID-190 Vaccine Study Group, Agrati, C., Castilletti, C., Goletti, D., Meschi, S., Sacchi, A., Matusali, G., Bordoni, V., Petrone, L., Lapa, D., Notari, S., Vanini, V., Colavita, F., Aiello, A., Agresta, A., Farroni, C., Grassi, G., Leone, S., Vaia, F., Capobianchi, M. R., Ippolito, G., and Puro, V.

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, SARS‐CoV2, QH301-705.5, Whole blood T cell assay, Microbiology, health care workers, Serology, 03 medical and health sciences, coordinate immunity, 0302 clinical medicine, Immune system, Virology, medicine, Health care worker, MRNA vaccine, 030212 general & internal medicine, Biology (General), Whole blood, biology, Transmission (medicine), business.industry, Public health, Brief Report, Coordinate immunity, Vaccination, 030104 developmental biology, mRNA vaccine, Cohort, Immunology, SARS-CoV2, biology.protein, Antibody, whole blood T cell assay, business
Abstract

Vaccination is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive worldwide scientific effort resulted in the rapid development of effective vaccines. This work aimed to define the dynamics of humoral and cell-mediated immune response in a cohort of health care workers (HCWs) who received a two-dose BNT162b2-mRNA vaccination. The serological response was evaluated by quantifying the anti-RBD and neutralizing antibodies. The cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2), produced in response to spike peptides. The BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune responses against spike peptides in virtually all HCWs without previous SARS-CoV-2 infection, with a moderate inverse relation with age in the anti-RBD response. Spike-specific T cells produced several Th1 cytokines (IFN-γ, TNF-α, and IL-2), which correlated with the specific-serological response. Overall, our study describes the ability of the BNT162b2 mRNA vaccine to elicit a coordinated neutralizing humoral and spike-specific T cell response in HCWs. Assessing the dynamics of these parameters by an easy immune monitoring protocol can allow for the evaluation of the persistence of the vaccine response in order to define the optimal vaccination strategy.

Published
2021

32. Immunogenicity and safety of BNT162b2 COVID-19 vaccine in a chronic lymphocytic leukaemia patient

Author

Francesca Colavita, Maria Rosaria Capobianchi, Michele Bibas, Giuseppe Ippolito, Concetta Castilletti, Chiara Agrati, Emanuele Nicastri, Alessandra Sacchi, Vincenzo Puro, Agrati, C., Castilletti, C., Sacchi, A., Colavita, F., Capobianchi, M. R., Puro, V., Nicastri, E., Ippolito, G., and Bibas, M.

Subjects
2019-20 coronavirus outbreak, Lymphocytic leukaemia, Coronavirus disease 2019 (COVID-19), business.industry, Immunogenicity, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Molecular Medicine, Medicine, Cell Biology, business, Virology, Letter to the Editor, Letter to the Editors
Published
2021

33. Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted in an Italian Reference Hospital

Author

Annalisa Mondi, Patrizia Lorenzini, Concetta Castilletti, Roberta Gagliardini, Eleonora Lalle, Angela Corpolongo, Maria Beatrice Valli, Fabrizio Taglietti, Stefania Cicalini, Laura Loiacono, Francesco Di Gennaro, Gianpiero D’Offizi, Fabrizio Palmieri, Emanuele Nicastri, Chiara Agrati, Nicola Petrosillo, Giuseppe Ippolito, Francesco Vaia, Enrico Girardi, Maria Rosaria Capobianchi, Andrea Antinori, Sara Zito, Maria Alessandra Abbonizio, Amina Abdeddaim, Elisabetta Agostini, Fabrizio Albarello, Gioia Amadei, Alessandra Amendola, Maria Assunta Antonica, Mario Antonini, Tommaso Ascoli Bartoli, Francesco Baldini, Raffaella Barbaro, Barbara Bartolini, Rita Bellagamba, Martina Benigni, Nazario Bevilacqua, Gianluigi Biava, Michele Bibas, Licia Bordi, Veronica Bordoni, Evangelo Boumis, Marta Branca, Rosanna Buonomo, Donatella Busso, Marta Camici, Paolo Campioni, Flaminia Canichella, Alessandro Capone, Cinzia Caporale, Emanuela Caraffa, Ilaria Caravella, Fabrizio Carletti, Adriana Cataldo, Stefano Cerilli, Carlotta Cerva, Roberta Chiappini, Pierangelo Chinello, Maria Assunta Cianfarani, Carmine Ciaralli, Claudia Cimaglia, Nicola Cinicola, Veronica Ciotti, Francesca Colavita, Massimo Cristofaro, Salvatore Curiale, Alessandra D’Abramo, Cristina Dantimi, Alessia De Angelis, Giada De Angelis, Maria Grazia De Palo, Federico De Zottis, Virginia Di Bari, Rachele Di Lorenzo, Federica Di Stefano, Davide Donno, Francesca Evangelista, Francesca Faraglia, Anna Farina, Federica Ferraro, Lorena Fiorentini, Andrea Frustaci, Matteo Fusetti, Vincenzo Galati, Paola Gallì, Gabriele Garotto, Ilaria Gaviano, Saba Gebremeskel Tekle, Maria Letizia Giancola, Filippo Giansante, Emanuela Giombini, Guido Granata, Maria Cristina Greci, Elisabetta Grilli, Susanna Grisetti, Gina Gualano, Fabio Iacomi, Marta Iaconi, Giuseppina Iannicelli, Carlo Inversi, Maria Elena Lamanna, Simone Lanini, Daniele Lapa, Luciana Lepore, Raffaella Libertone, Raffaella Lionetti, Giuseppina Liuzzi, Andrea Lucia, Franco Lufrani, Manuela Macchione, Gaetano Maffongelli, Alessandra Marani, Luisa Marchioni, Andrea Mariano, Maria Cristina Marini, Micaela Maritti, Annelisa Mastrobattista, Ilaria Mastrorosa, Giulia Matusali, Valentina Mazzotta, Paola Mencarini, Silvia Meschi, Francesco Messina, Sibiana Micarelli, Giulia Mogavero, Marzia Montalbano, Chiara Montaldo, Silvia Mosti, Silvia Murachelli, Maria Musso, Michela Nardi, Assunta Navarra, Martina Nocioni, Pasquale Noto, Roberto Noto, Alessandra Oliva, Ilaria Onnis, Sandrine Ottou, Claudia Palazzolo, Emanuele Pallini, Giulio Palombi, Carlo Pareo, Virgilio Passeri, Federico Pelliccioni, Giovanna Penna, Antonella Petrecchia, Ada Petrone, Elisa Pianura, Carmela Pinnetti, Maria Pisciotta, Pierluca Piselli, Silvia Pittalis, Agostina Pontarelli, Costanza Proietti, Vincenzo Puro, Paolo Migliorisi Ramazzini, Alessia Rianda, Gabriele Rinonapoli, Silvia Rosati, Dorotea Rubino, Martina Rueca, Alberto Ruggeri, Alessandra Sacchi, Alessandro Sampaolesi, Francesco Sanasi, Carmen Santagata, Alessandra Scarabello, Silvana Scarcia, Vincenzo Schininà, Paola Scognamiglio, Laura Scorzolini, Giulia Stazi, Giacomo Strano, Chiara Taibi, Giorgia Taloni, Tetaj Nardi, Roberto Tonnarini, Simone Topino, Martina Tozzi, Francesco Vairo, Alessandra Vergori, Laura Vincenzi, Ubaldo Visco-Comandini, Serena Vita, Pietro Vittozzi, Mauro Zaccarelli, Antonella Zanetti, Mondi, A., Lorenzini, P., Castilletti, C., Gagliardini, R., Lalle, E., Corpolongo, A., Valli, M. B., Taglietti, F., Cicalini, S., Loiacono, L., Di Gennaro, F., D'Offizi, G., Palmieri, F., Nicastri, E., Agrati, C., Petrosillo, N., Ippolito, G., Vaia, F., Girardi, E., Capobianchi, M. R., Antinori, A., Zito, S., Abbonizio, M. A., Abdeddaim, A., Agostini, E., Albarello, F., Amadei, G., Amendola, A., Antonica, M. A., Antonini, M., Bartoli, T. A., Baldini, F., Barbaro, R., Bartolini, B., Bellagamba, R., Benigni, M., Bevilacqua, N., Biava, G., Bibas, M., Bordi, L., Bordoni, V., Boumis, E., Branca, M., Buonomo, R., Busso, D., Camici, M., Campioni, P., Canichella, F., Capone, A., Caporale, C., Caraffa, E., Caravella, I., Carletti, F., Cataldo, A., Cerilli, S., Cerva, C., Chiappini, R., Chinello, P., Cianfarani, M. A., Ciaralli, C., Cimaglia, C., Cinicola, N., Ciotti, V., Colavita, F., Cristofaro, M., Curiale, S., D'Abramo, A., Dantimi, C., De Angelis, A., De Angelis, G., De Palo, M. G., De Zottis, F., Di Bari, V., Di Lorenzo, R., Di Stefano, F., Donno, D., Evangelista, F., Faraglia, F., Farina, A., Ferraro, F., Fiorentini, L., Frustaci, A., Fusetti, M., Galati, V., Galli, P., Garotto, G., Gaviano, I., Tekle, S. G., Giancola, M. L., Giansante, F., Giombini, E., Granata, G., Greci, M. C., Grilli, E., Grisetti, S., Gualano, G., Iacomi, F., Iaconi, M., Iannicelli, G., Inversi, C., Lamanna, M. E., Lanini, S., Lapa, D., Lepore, L., Libertone, R., Lionetti, R., Liuzzi, G., Lucia, A., Lufrani, F., Macchione, M., Maffongelli, G., Marani, A., Marchioni, L., Mariano, A., Marini, M. C., Maritti, M., Mastrobattista, A., Mastrorosa, I., Matusali, G., Mazzotta, V., Mencarini, P., Meschi, S., Messina, F., Micarelli, S., Mogavero, G., Montalbano, M., Montaldo, C., Mosti, S., Murachelli, S., Musso, M., Nardi, M., Navarra, A., Nocioni, M., Noto, P., Noto, R., Oliva, A., Onnis, I., Ottou, S., Palazzolo, C., Pallini, E., Palombi, G., Pareo, C., Passeri, V., Pelliccioni, F., Penna, G., Petrecchia, A., Petrone, A., Pianura, E., Pinnetti, C., Pisciotta, M., Piselli, P., Pittalis, S., Pontarelli, A., Proietti, C., Puro, V., Ramazzini, P. M., Rianda, A., Rinonapoli, G., Rosati, S., Rubino, D., Rueca, M., Ruggeri, A., Sacchi, A., Sampaolesi, A., Sanasi, F., Santagata, C., Scarabello, A., Scarcia, S., Schinina, V., Scognamiglio, P., Scorzolini, L., Stazi, G., Strano, G., Taibi, C., Taloni, G., Nardi, T., Tonnarini, R., Topino, S., Tozzi, M., Vairo, F., Vergori, A., Vincenzi, L., Visco-Comandini, U., Vita, S., Vittozzi, P., Zaccarelli, M., and Zanetti, A.

Subjects
Male, 0301 basic medicine, Time Factors, medicine.medical_treatment, Respiratory System, coronavirus, Infectious and parasitic diseases, RC109-216, Severity of Illness Index, Cohort Studies, 0302 clinical medicine, risk factors, 030212 general & internal medicine, Respiratory disease, General Medicine, Middle Aged, Virus Shedding, Infectious Diseases, symbols, RNA, Viral, Female, Coronavirus, COVID-19, viral clearance, viral shedding, Risk factors, SARS-CoV-2, Cohort study, Adult, Microbiology (medical), medicine.medical_specialty, viral shedding, Coronaviru, 030106 microbiology, Article, NO, 03 medical and health sciences, symbols.namesake, Internal medicine, Severity of illness, medicine, Humans, Poisson regression, Aged, Proportional Hazards Models, Mechanical ventilation, business.industry, Proportional hazards model, COVID-19, Retrospective cohort study, medicine.disease, Respiratory failure, Risk factor, business, viral clearance
Abstract

Background Few data about predictors and outcomes associated with prolonged SARS-CoV-2 RNA shedding (VS) are available. Methods Retrospective study including all patients admitted with COVID-19 in an Italian reference hospital for infectious diseases between March 1 and July 1, 2020. Predictors of viral clearance (VC) and prolonged VS from upper respiratory tract were assessed by Poisson regression and logistic regression analyses. The causal relation between duration of VS and probability of clinical outcomes was evaluated through inverse probability weighted Cox model. Results 536 subjects were included. Median duration of VS from symptoms onset was 18 days (IQR 12-26). The estimated 30-day probability of VC was 70.2% (95%CI:65-75). At multivariable analysis, patients with comorbidities (aIRR = 0.88, p = 0.004), lymphopenia at hospital admission (aIRR = 0.75, p = 0.032) and with moderate/severe respiratory disease (aIRR = 0.42, p 1000 ng/mL at admission (aOR = 1.76, p = 0.035) independently predicted prolonged VS. The achievement of VC doubled the chance of clinical recovery (aHR = 2.17, p

Published
2021

34. Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity

Author

Alessandra Sacchi, Veronica Bordoni, Maria Giovanna Desimio, Concetta Castilletti, Sara De Minicis, Giuseppe Ippolito, Margherita Doria, Maria Rosaria Capobianchi, Rita Casetti, Eleonora Cimini, Germana Grassi, Chiara Agrati, Francesca Colavita, Cimini, E., Sacchi, A., De Minicis, S., Bordoni, V., Casetti, R., Grassi, G., Colavita, F., Castilletti, C., Capobianchi, M. R., Ippolito, G., Desimio, M. G., Doria, M., and Agrati, C.

Subjects
0301 basic medicine, Microbiology (medical), Vδ2 T-cell, Cytotoxicity, Microbiology, Article, NKG2D, 03 medical and health sciences, 0302 clinical medicine, Immune system, Virology, Cytotoxic T cell, 030212 general & internal medicine, Antiviral activity, innate immunity, lcsh:QH301-705.5, perforin, ZIKV, Vδ2 T-cells, A549 cell, Innate immunity, Innate immune system, biology, Chemistry, Perforin, Degranulation, 030104 developmental biology, lcsh:Biology (General), biology.protein, antiviral activity, cytotoxicity
Abstract

An expansion of effector/activated V&delta, 2 T-cells was recently described in acute Zika virus (ZIKV)-infected patients, but their role in the protective immune response was not clarified. The aim of this study was to define the antiviral activity of V&delta, 2 T-cells against ZIKV-infected cells. The V&delta, 2 T-cells expansion and their cytotoxic activity against ZIKV-infected cells were tested in vitro and analyzed by RT-PCR and flow cytometry. We found that ZIKV infection was able to induce V&delta, 2 T-cells expansion and sensitized A549 cells to V&delta, 2-mediated killing. Indeed, expanded V&delta, 2 T-cells killed ZIKV-infected cells through degranulation and perforin release. Moreover, ZIKV infection was able to increase the expression on A549 cells of NKG2D ligands (NKG2DLs), namely MICA, MICB, and ULBP2, at both the mRNA and protein levels, suggesting the possible involvement of these molecules in the recognition by NKG2D-expressing V&delta, 2 T-cells. Indeed, the killing of ZIKV-infected cells by expanded V&delta, 2 T-cells was mediated by NKG2D/NKG2DL interaction as NKG2D neutralization abrogated V&delta, 2 cytotoxicity. Our data showed a strong antiviral activity of V&delta, 2 T-cells against ZIKV-infected cells, suggesting their involvement in the protective immune response. Other studies are necessary to investigate whether the lack of V&delta, 2 T-cells expansion in vivo may be associated with disease complications.

Published
2019

35. COVID-eVax, an electroporated DNA vaccine candidate encoding the SARS-CoV-2 RBD, elicits protective responses in animal models

Author

Abraham Nyska, Alessia Muzi, Fabio Palombo, Luigi Aurisicchio, Mirela Kuka, Nicola Clementi, Concetta Castilletti, Valerio Chiarini, Erika Salvatori, Emanuele Marra, Alina Seidel, Francesca Colavita, Roberto Arriga, Valeria Fumagalli, Giulia Matusali, Laura Luberto, Lorena Donnici, Maria Lucrezia Pacello, Davide Marotta, Fabiana Fosca Ferrara, Eleonora Sala, Amy Rose Challis, Nicasio Mancini, Mariano Maffei, Eleonora Pinto, Gennaro Ciliberto, Emiliano Pavoni, Daniela Stoppoloni, Giuseppe Roscilli, Matteo Iannacone, Emanuela D’Acunto, Lucia Lione, Rüdiger Groß, Lukas Wettstein, Antonella Conforti, Federica Bucci, Elisa Bono, Jemma Paterson, Maria Rosaria Capobianchi, Gianfranco Caselli, Kathryn A. Ryan, Grazia Vitagliano, Jan Münch, Lucio C. Rovati, Matteo Conti, Giuseppe Ippolito, Elena Criscuolo, Chiara Perucchini, Micol Ravà, Manuela Cappelletti, Pietro Di Lucia, Leonardo Giustini, Raffaele De Francesco, Luca G. Guidotti, Mirco Compagnone, Conforti, A., Marra, E., Palombo, F., Roscilli, G., Rava, M., Fumagalli, V., Muzi, A., Maffei, M., Luberto, L., Lione, L., Salvatori, E., Compagnone, M., Pinto, E., Pavoni, E., Bucci, F., Vitagliano, G., Stoppoloni, D., Pacello, M. L., Cappelletti, M., Ferrara, F. F., D'Acunto, E., Chiarini, V., Arriga, R., Nyska, A., Di Lucia, P., Marotta, D., Bono, E., Giustini, L., Sala, E., Perucchini, C., Paterson, J., Ryan, K. A., Challis, A. -R., Matusali, G., Colavita, F., Caselli, G., Criscuolo, E., Clementi, N., Mancini, N., Gross, R., Seidel, A., Wettstein, L., Munch, J., Donnici, L., Conti, M., De Francesco, R., Kuka, M., Ciliberto, G., Castilletti, C., Capobianchi, M. R., Ippolito, G., Guidotti, L. G., Rovati, L., Iannacone, M., and Aurisicchio, L.

Subjects
Genetically modified mouse, DNA vaccine, COVID-19 Vaccines, Mice, Transgenic, Antibodies, Viral, DNA vaccination, Rats, Sprague-Dawley, Mice, Plasmid, Protein Domains, Complementary DNA, Drug Discovery, Genetics, Vaccines, DNA, Animals, Humans, Neutralizing antibody, Molecular Biology, Pharmacology, Mice, Inbred BALB C, biology, SARS-CoV-2, Electroporation, Immunogenicity, Ferrets, COVID-19, protection, Virology, Antibodies, Neutralizing, animal models, antiviral immunity, Mice, Inbred C57BL, Viral replication, Models, Animal, Spike Glycoprotein, Coronavirus, biology.protein, Molecular Medicine, Female, Immunization, Original Article
Abstract

The COVID-19 pandemic caused by SARS-CoV-2 has made the development of safe and effective vaccines a critical priority. To date, four vaccines have been approved by European and American authorities for preventing COVID-19, but the development of additional vaccine platforms with improved supply and logistics profiles remains a pressing need. Here we report the preclinical evaluation of a novel COVID-19 vaccine candidate based on the electroporation of engineered, synthetic cDNA encoding a viral antigen in the skeletal muscle. We constructed a set of prototype DNA vaccines expressing various forms of the SARS-CoV-2 spike (S) protein and assessed their immunogenicity in animal models. Among them, COVID-eVax—a DNA plasmid encoding a secreted monomeric form of SARS-CoV-2 S protein receptor-binding domain (RBD)—induced the most potent anti-SARS-CoV-2 neutralizing antibody responses (including against the current most common variants of concern) and a robust T cell response. Upon challenge with SARS-CoV-2, immunized K18-hACE2 transgenic mice showed reduced weight loss, improved pulmonary function, and lower viral replication in the lungs and brain. COVID-eVax conferred significant protection to ferrets upon SARS-CoV-2 challenge. In summary, this study identifies COVID-eVax as an ideal COVID-19 vaccine candidate suitable for clinical development. Accordingly, a combined phase I-II trial has recently started., Graphical abstract, We report the development, characterization, and preclinical evaluation of COVID-eVax, a novel COVID-19 vaccine candidate with improved supply and logistics profiles. The technology is based on the electroporation of engineered, synthetic cDNA encoding a secreted monomeric form of the receptor-binding domain of the SARS-CoV-2 spike protein.

Full Text
View/download PDF

37. Impact of COVID-19 vaccines in patients on hemodialysis: an Italian multicentre cohort study.

Author

De Masi S, Da Cas R, Ippolito FM, Baglio G, Zoccali C, Chiarotti F, Fabiani M, Colavita F, Castilletti C, Salomone M, Mele A, and Messa P

Abstract

Background: The aim of this study was to evaluate the impact on the national health system of COVID-19 infection in vaccinated patients undergoing haemodialysis., Methods: From the cohort of vaccinated dialysis patients enrolled in 118 dialysis centres, we calculated hospitalisation incidence in COVID-19-infected subjects. COVID-19-related hospitalisations and ICU admissions were analysed over two time periods (prior to administration of the third dose and following administration of the third dose of vaccine) and adjusted for several co-variates. Using the general population as the reference, we then calculated the Standardized Incidence Ratio (SIR) of hospitalisation., Results: Eighty-two subjects out of 1096 infected patients were hospitalised (7.5%) and sixty-four hospitalisations occurred among the 824 infected persons after the third dose. Age ≥ 60 years (Adj RR 2.91; 95% CI 1.34-6.30) and lung disease (Adj RR = 2.45; 95% CI 1.32-4.54) were the only risk factors associated with hospitalisation. The risk of ICU admission in the second time period (Time 2) was reduced by 86% (RR = 0.14; 95% CI 0.03-0.71) compared to the first time period (Time 1). The SIR of hospitalisation (SIR 14.51; 95% CI 11.37-17.65) and ICU admission (SIR 14.58; 95% CI 2.91-26.24) showed an increase in the number of events in dialysis patients compared to the general population., Conclusions: Our analysis revealed that while the second variant of the virus increased infection rates, it was concurrently associated with mitigated severity of infections. Dialysis patients exhibited a higher susceptibility to both COVID-19 hospitalisation and ICU admission than the general population throughout the pandemic., (© 2024. The Author(s) under exclusive licence to Italian Society of Nephrology.)

Published
2024
Full Text
View/download PDF

38. MPXV DNA kinetics in bloodstream and other body fluids samples.

Author

Meschi S, Colavita F, Carletti F, Mazzotta V, Matusali G, Specchiarello E, Ascoli Bartoli T, Mondi A, Minosse C, Giancola ML, Pinnetti C, Valli MB, Lapa D, Mizzoni K, Sullivan DJ, Ou J, Focosi D, Girardi E, Nicastri E, Antinori A, and Maggi F

Subjects
Humans, Male, Kinetics, Semen virology, Mpox (monkeypox) virology, Mpox (monkeypox) epidemiology, Mpox (monkeypox) diagnosis, Saliva virology, Female, Adult, Virus Shedding, Middle Aged, DNA, Viral genetics, Viral Load, Body Fluids virology, Monkeypox virus genetics, Monkeypox virus isolation & purification
Abstract

Since spring 2022, the global epidemiology of the monkeypox virus (MPXV) has changed. The unprecedented increase of human clade II MPXV cases worldwide heightened concerns about this emerging zoonotic disease. We analysed the positivity rates, viral loads, infectiousness, and persistence of MPXV DNA for up to 4 months in several biological samples from 89 MPXV-confirmed cases. Our data showed that viral loads and positivity rates were higher during the first two weeks of symptoms for all sample types. Amongst no-skin-samples, respiratory specimens showed higher MPXV DNA levels and median time until viral clearance, suggesting their usefulness in supporting MPXV diagnosis, investigating asymptomatic patients, and monitoring viral shedding. Infectious virus was cultured from respiratory samples, semen, and stools, with high viral loads and collected within the first 10 days. Notably, only one saliva and one semen were found positive for viral DNA after 71 and 31 days from symptoms, respectively. The focus on bloodstream samples showed the best testing sensitivity in plasma, reporting the overall highest MPXV DNA detection rate and viral loads during the 3-week follow-up as compared to serum and whole-blood. The data here presented can be useful for MPXV diagnostics and a better understanding of the potential alternative routes of its onward transmission., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

39. JN.1 neutralizing antibody titers after XBB.1.5 monovalent vaccine boost in healthcare workers and people with HIV.

Author

Matusali G, Mazzotta V, Meschi S, Colavita F, Gagliardini R, Bettini A, Gruber CEM, Vergori A, Gallì P, Focosi D, Girardi E, Antinori A, and Maggi F

Subjects
Humans, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, Adult, Male, Female, COVID-19 prevention & control, COVID-19 immunology, Immunization, Secondary, HIV Antibodies blood, HIV Antibodies immunology, Middle Aged, SARS-CoV-2 immunology, Health Personnel, HIV Infections immunology, HIV Infections prevention & control, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology
Published
2024
Full Text
View/download PDF

40. Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.

Author

Matusali G, Vergori A, Cimini E, Mariotti D, Mazzotta V, Lepri AC, Colavita F, Gagliardini R, Notari S, Meschi S, Fusto M, Tartaglia E, Girardi E, Maggi F, and Antinori A

Subjects
Humans, Immunization Programs, RNA, Messenger, Seasons, mRNA Vaccines, Antibodies, Neutralizing, Antibodies, Viral, COVID-19 prevention & control, HIV Infections
Abstract

We estimated the dynamics of the neutralizing response against XBB sublineages and T cell response in persons with HIV (PWH) with previous AIDS and/or CD4 < 200/mm 3 receiving the bivalent original strain/BA.4-5 booster dose in fall 2022. Samples were collected before the shot (Day 0), 15 days, 3, and 6 months after. PWH were stratified by immunization status: hybrid immunity (HI; vaccination plus COVID-19) versus nonhybrid immunity (nHI; vaccination only). Fifteen days after the booster, 16% and 30% of PWH were nonresponders in terms of anti-XBB.1.16 or anti-EG.5.1 nAbs, respectively. Three months after, a significant waning of anti-XBB.1.16, EG.5.1 and -XBB.1 nAbs was observed both in HI and nHI but nAbs in HI were higher than in nHI. Six months after both HI and nHI individuals displayed low mean levels of anti-XBB.1.16 and EG.5.1 nAbs. Regarding T cell response, IFN-γ values were stable over time and similar in HI and nHI. Our data showed that in PWH, during the prevalent circulation of the XBB.1.16, EG.5.1, and other XBB sublineages, a mRNA bivalent vaccine might not confer broad protection against them. With a view to the 2023/2024 vaccination campaign, the use of the monovalent XBB.1.5 mRNA vaccine should be urgently warranted in PWH to provide adequate protection., (© 2024 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)

Published
2024
Full Text
View/download PDF

41. Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study.

Author

Mazzotta V, Lepri AC, Matusali G, Cimini E, Piselli P, Aguglia C, Lanini S, Colavita F, Notari S, Oliva A, Meschi S, Casetti R, Mondillo V, Vergori A, Bettini A, Grassi G, Pinnetti C, Lapa D, Tartaglia E, Gallì P, Mondi A, Montagnari G, Gagliardini R, Nicastri E, Lichtner M, Sarmati L, Tamburrini E, Mastroianni C, Stingone C, Siddu A, Barca A, Fontana C, Agrati C, Girardi E, Vaia F, Maggi F, and Antinori A

Abstract

Background: Pre-exposure vaccination with MVA-BN has been widely used against mpox to contain the 2022 outbreak. Many countries have defined prioritized strategies, administering a single dose to those historically vaccinated for smallpox, to achieve quickly adequate coverage in front of low supplies. Using epidemiological models, real-life effectiveness was estimated at approximately 36%-86%, but no clinical trials were performed. Few data on MVA-BN immunogenicity are currently available, and there are no established correlates of protection. Immunological response in PLWH in the context of the 2022 outbreak was also poorly described., Methods: Blood samples were collected from participants eligible for pre-exposure MVA-BN vaccination before (T1) receiving a full course of vaccine (single-dose for vaccine-experienced or smallpox-primed and two-dose for smallpox vaccine-naïve or smallpox non-primed) and one month after the last dose (T2 and T3, respectively). MPXV-specific IgGs were measured by in-house immunofluorescence assay, using 1:20 as screening dilution, MPXV-specific nAbs by 50% plaque reduction neutralization test (PRNT 50 , starting dilution 1:10), and IFN-γ-producing specific T cells to MVA-BN vaccine, by ELISpot assay. Paired or unpaired t-test and Wilcoxon or Mann-Whitney test were used to analyse IgG and nAbs, and T-cell response, as appropriate. The probability of IgG and nAb response in vaccine-experienced vs. vaccine-naïve was estimated in participants not reactive at T1. The McNemar test was used to evaluate vaccination's effect on humoral response both overall and by smallpox vaccination history. In participants who were not reactive at T1, the proportion of becoming responders one month after full-cycle completion by exposure groups was compared by logistic regression and then analysed by HIV status strata (interaction test). The response was also examined in continuous, and the Average Treatment Effect (ATE) of the difference from baseline to schedule completion according to previous smallpox vaccination was estimated after weighting for HIV using a linear regression model. Self-reports of adverse effects following immunization (AEFIs) were prospectively collected after the first MVA-BN dose (T1). Systemic (S-AEFIs: fatigue, myalgia, headache, GI effects, chills) and local (L-AEFIs: redness, swelling, pain) AEFIs were graded as absent (grade 0), mild (1), moderate (2), or severe (3). The maximum level of severity for S-AEFIs and L-AEFIs ever experienced over the 30 days post-dose by vaccination exposure groups were analysed using a univariable multinomial logistic regression model and after adjusting for HIV status; for each of the symptoms, we also compared the mean duration by exposure group using an unpaired t-test., Findings: Among the 164 participants included, 90 (54.8%) were smallpox vaccine-experienced. Median age was 49 years (IQR 41-55). Among the 76 (46%) PLWH, 76% had a CD4 count >500 cells/μL. There was evidence that both the IgG and nAbs titers increased after administration of the MVA-BN vaccine. However, there was no evidence for a difference in the potential mean change in humoral response from baseline to the completion of a full cycle when comparing primed vs. non-primed participants. Similarly, there was no evidence for a difference in the seroconversion rate after full cycle vaccination in the subset of participants not reactive for nAbs at T1 (p = 1.00 by Fisher's exact test). In this same analysis and for the nAbs outcome, there was some evidence of negative effect modification by HIV (interaction p-value = 0.17) as primed people living with HIV (PLWH) showed a lower probability of seroconversion vs. non-primed, and the opposite was seen in PLWoH. When evaluating the response in continuous, we observed an increase in T-cell response after MVA-BN vaccination in both primed and non-primed. There was evidence for a larger increase when using the 2-dose vs. one-dose strategy with a mean difference of -2.01 log 2 (p ≤ 0.0001), after controlling for HIV. No evidence for a difference in the risk of developing any AEFIs of any grade were observed by exposure group, except for the lower risk of grade 2 (moderate) fatigue, induration and local pain which was lower in primed vs. non-primed [OR 0.26 (0.08-0.92), p = 0.037; OR 0.30 (0.10-0.88), p = 0.029 and OR 0.19 (0.05-0.73), p = 0.015, respectively]. No evidence for a difference in symptom duration was also detected between the groups., Interpretation: The evaluation of the humoral and cellular response one month after the completion of the vaccination cycle suggested that MVA-BN is immunogenic and that the administration of a two-dose schedule is preferable regardless of the previous smallpox vaccination history, especially in PLWH, to maximize nAbs response. MVA-BN was safe as well tolerated, with grade 2 reactogenicity higher after the first administration in vaccine-naïve than in vaccine-experienced individuals, but with no evidence for a difference in the duration of these adverse effects. Further studies are needed to evaluate the long-term duration of immunity and to establish specific correlates of protection., Funding: The study was supported by the National Institute for Infectious Disease Lazzaro Spallanzani IRCCS "Advanced grant 5 × 1000, 2021" and by the Italian Ministry of Health " Ricerca Corrente Linea 2 "., Competing Interests: The authors declare that no conflicting financial interests or other competing relationships exist., (© 2023 The Author(s).)

Published
2024
Full Text
View/download PDF

43. Association between sex hormones and anti-S/RBD antibody responses to COVID-19 vaccines in healthcare workers.

Author

Anticoli S, Dorrucci M, Iessi E, Chiarotti F, Di Prinzio RR, Vinci MR, Zaffina S, Puro V, Colavita F, Mizzoni K, Meschi S, Vonesch N, Albano C, Ortona E, Ruggieri A, and Tomao P

Subjects
Humans, Female, Male, COVID-19 Vaccines, Vaccination, Gonadal Steroid Hormones, Antibodies, Neutralizing, Health Personnel, Antibodies, Viral, Antibody Formation, COVID-19 prevention & control
Abstract

Healthcare workers (HCWs) are the target population for vaccination against coronavirus disease (COVID-19) as they are at a high risk of exposure and transmission of pathogens to patients. Neutralizing antibodies developed after COVID-19 vaccination decline within few months of vaccination. Several factors, including age and sex, can affect the intensity, efficacy, and duration of immune response to vaccines. However, sex-specific analyses of humoral responses to COVID-19 vaccines are lacking. This study aimed to evaluate sex-based differences in anti-S/RBD (Receptor Binding Domain) responses at three different time points after the second dose of mRNA COVID-19 vaccine in HCWs in relation to age, and to investigate the role of sex hormones as potential markers of response. Anti-S/RBD levels after two doses of the mRNA vaccine were collected from 521 HCWs naïve to COVID-19, working at two Italian Clinical Centers. Multiple regression analysis was applied to evaluate the association between anti-S levels and sex, age, and plasma levels of sex hormones. Significantly higher anti-S/RBD response to the COVID-19 vaccination was found in female HCWs, and a significant and more abrupt decline in response with time was observed in women than that in men. A novel, positive association of testosterone plasma levels and higher anti-S levels in male HCWs was found, suggesting its potential role as sex specific marker in males. In conclusion, understanding the sex-based differences in humoral immune responses to vaccines may potentially improve vaccination strategies and optimize surveillance programs for HCWs.

Published
2023
Full Text
View/download PDF

44. Long Term Assessment of Anti-SARS-CoV-2 Immunogenicity after mRNA Vaccine in Persons Living with HIV.

Author

Vergori A, Cozzi-Lepri A, Matusali G, Cicalini S, Bordoni V, Meschi S, Mazzotta V, Colavita F, Fusto M, Cimini E, Notari S, D'Aquila V, Lanini S, Lapa D, Gagliardini R, Mariotti D, Giannico G, Girardi E, Vaia F, Agrati C, Maggi F, and Antinori A

Abstract

(1) Background: Waning of neutralizing and cell-mediated immune response after the primary vaccine cycle (PVC) and the first booster dose (BD) is of concern, especially for PLWH with a CD4 count ≤200 cells/mm 3 . (2) Methods: Neutralizing antibodies (nAbs) titers by microneutralization assay against WD614G/Omicron BA.1 and IFNγ production by ELISA assay were measured in samples of PLWH at four time points [2 and 4 months post-PVC (T1 and T2), 2 weeks and 5 months after the BD (T3 and T4)]. Participants were stratified by CD4 count after PVC (LCD4, ≤200/mm 3 ; ICD4, 201-500/mm 3 , and HCD4, >500/mm 3 ). Mixed models were used to compare mean responses over T1-T4 across CD4 groups. (3) Results: 314 PLWH on ART (LCD4 = 56; ICD4 = 120; HCD4 = 138) were enrolled. At T2, levels of nAbs were significantly lower in LCD4 vs. ICD4/HCD4 ( p = 0.04). The BD was crucial for increasing nAbs titers above 1:40 at T3 and up to T4 for WD614G. A positive T cell response after PVC was observed in all groups, regardless of CD4 ( p = 0.31). (4) Conclusions: Waning of nAbs after PVC was more important in LCD4 group. The BD managed to re-establish higher levels of nAbs against WD614G, which were retained for 5 months, but for shorter time for Omicron BA.1. The T cellular response in the LCD4 group was lower than that seen in participants with higher CD4 count, but, importantly, it remained above detectable levels over the entire study period.

Published
2023
Full Text
View/download PDF

46. Evaluation of Cross-Immunity to the Mpox Virus Due to Historic Smallpox Vaccination.

Author

Matusali G, Petruccioli E, Cimini E, Colavita F, Bettini A, Tartaglia E, Sbarra S, Meschi S, Lapa D, Francalancia M, Bordi L, Mazzotta V, Coen S, Mizzoni K, Beccacece A, Nicastri E, Pierelli L, Antinori A, Girardi E, Vaia F, Sette A, Grifoni A, Goletti D, Puro V, and Maggi F

Abstract

When the Mpox virus (MPXV) began spreading globally in 2022, it became critical to evaluate whether residual immunity from smallpox vaccination provided cross-protection. To assess the cross-immune response to MPXV, we collected serum samples ( n = 97) and PBMCs ( n = 30) from healthy-donors, either born before 1974 and reporting smallpox vaccination during childhood or born after 1975 and not vaccinated with Vaccinia virus (VACV)-based vaccines. We evaluated the levels of anti-MPXV IgG and neutralizing antibodies (Nabs) and the presence of a T cell response against MPXV. We found anti-MPXV IgG and Nabs in 60 (89.6%) and 40 (70.1%) vaccinated individuals, respectively. We observed a T cell response to Orthopoxviruses and MPXV peptide pools in 30% of vaccinated individuals. We thus show that a high proportion of subjects who received the smallpox vaccine 40 to 60 years ago have humoral cross-immunity, while the T-cell-specific response against MPXV was observed in a smaller group (30%) of vaccinated individuals. This study, combined with information on immunity developed during natural infection or the administration of current vaccines, will contribute to a better understanding of humoral and cellular responses against MPXV., Competing Interests: The authors declare no conflicts of interest.

Published
2023
Full Text
View/download PDF

47. Safety and efficacy of COVID-19 vaccines in patients on dialysis: a multicentre cohort study in Italy.

Author

Menniti-Ippolito F, Mele A, Da Cas R, De Masi S, Chiarotti F, Fabiani M, Baglio G, Traversa G, Colavita F, Castilletti C, Salomone M, Zoccali C, and Messa P

Subjects
Humans, Cohort Studies, Italy epidemiology, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 Vaccines, Renal Dialysis
Abstract

Background: The aim of this study was to evaluate the efficacy and safety of COVID-19 vaccines in patients undergoing haemodialysis in Italy compared to the general population., Methods: In this cohort study, 118 dialysis centres from 18 Italian Regions participated. Individuals older than 16 years on dialysis treatment for at least 3 months, who provided informed consent were included. We collected demographic and clinical information, as well as data on vaccination status, hospitalisations, access to intensive care units and adverse events. We calculated the incidence, hospitalisation, mortality, and fatality rates in the vaccinated dialysis cohort, adjusted for several covariates. The incidence rates of infection in the dialysis cohort and the general population were compared through Standardised Incidence Rate Ratio., Results: The study included 6555 patients vaccinated against SARS-CoV-2 infection according to the schedule recommended in Italy. Between March 2021 and May 2022, there were 1096 cases of SARS-CoV-2 infection, with an incidence rate after completion of the three-dose vaccination cycle of 37.7 cases per 100 person-years. Compared to the general population, we observed a 14% reduction in the risk of infection for patients who received three vaccine doses (Standardised Incidence Rate Ratio: 0.86; 95% Confidence Interval: 0.81-0.91), whereas no statistically significant differences were found for COVID-19-related hospitalisations, intensive care unit admissions or death. No safety signals emerged from the reported adverse events., Conclusions: The vaccination program against SARS-CoV-2 in the haemodialysis population showed an effectiveness and safety profile comparable to that seen in the general population., (© 2023. The Author(s) under exclusive licence to Italian Society of Nephrology.)

Published
2023
Full Text
View/download PDF

48. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.

Author

Vergori A, Matusali G, Lepri AC, Cimini E, Fusto M, Colavita F, Gagliardini R, Notari S, Mazzotta V, Mariotti D, Cicalini S, Girardi E, Vaia F, Maggi F, and Antinori A

Subjects
Humans, COVID-19 Vaccines, T-Lymphocytes, SARS-CoV-2, Vaccines, Synthetic, Vaccines, Combined, Antibodies, Neutralizing, Antibodies, Viral, mRNA Vaccines, Acquired Immunodeficiency Syndrome, COVID-19 prevention & control
Abstract

Objectives: To investigate immunogenicity of SARS-CoV-2 vaccine third booster dose (3BD; fifth dose) with bivalent vaccine original/BA4/5 vaccine in people living with HIV (PLWH)., Methods: This is an observational cohort study to evaluate the outcomes of SARS-CoV-2 vaccination (HIV-VAC study). We analyzed microneutralization assay and interferon-γ production in 48 PLWH on antiretroviral therapy with clusters of differentiation (CD4) count <200 cell/mm 3 and/or previous AIDS according to immunization status: vaccinated PLWH who had a previous SARS-CoV-2 infection (hybrid immunization, HI) vs those only vaccinated (non-hybrid immunization, nHI) and current CD4 count., Results: After 15 days from its administration (T1), the 3BD bivalent messenger RNA vaccine elicited a statistically significant increase of neutralizing antibodies (nAbs) geometric mean titers from T0 to T1 against W-D614G (fold increase 4.8; P <0.0001), BA.5 (8.6 P <0.0001), BQ.1.1 (6.4, P <0.0001) and XBB.1 (6.5, P <0.0001). When compared to BA.5, nAbs geometric mean titers against BQ.1.1 and XBB.1 decreased by 3.5 and 4.1-fold, respectively. After controlling for age, years from AIDS diagnosis, CD4 count at administration and CD4 count nadir, the fold change reduction in nAbs response to other variants of concerns as compared to BA.1, was larger in participants with HI vs those nHI: 0.59 lower (95% confidence interval 0.36-0.97, P = 0.04) for BQ.1.1 and 0.67 lower (95% confidence interval: 0.47-0.96, P = 0.03) for XBB.1. In contrast, the analysis carried little evidence for an association between current CD4 count and response to the fifth dose of bivalent vaccine. Furthermore, cell-mediated immunity remained stable., Conclusion: Our data support the current recommendation of offering bivalent mRNA vaccine booster doses to PLWH with low CD4 count or previous AIDS at first vaccination, especially in those who never previously acquired SARS-CoV-2 and regardless of current CD4 count., Competing Interests: Declarations of Competing Interest The authors have no competing interests to declare., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)

Published
2023
Full Text
View/download PDF

49. Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak.

Author

Colavita F, Matusali G, Mazzotta V, Bettini A, Lapa D, Meschi S, Francalancia M, Pinnetti C, Bordi L, Mizzoni K, Coen S, Girardi E, Vaia F, Nicastri E, Antinori A, and Maggi F

Subjects
Humans, Immunoglobulin G, Immunoglobulin M, Antibody Formation, Antibodies, Viral, Antibodies, Neutralizing, Immunoglobulin A, Disease Outbreaks, Monkeypox virus, Smallpox
Abstract

Information on the immune response during the mpox virus (MPXV) infection is still scarce or limited to past studies when cross-reactive immunity from smallpox vaccination was predominant. Here, we describe the short-term kinetics of the antibody response in patients with acute MPXV infection during the 2022 multicountry outbreak. A total of 64 samples from 18 MPXV-positive patients were longitudinally collected from the day of symptom onset (DSO) up to 20 days after and tested for anti-MPXV immunoglobulin G (IgG), IgM, IgA, and neutralizing antibodies (nAb) using the whole-live virus isolated in May 2022. IgG, IgM, and IgA were detected as early as 4 DSO (median time of seroconversion 7.5 DSO for IgG, 8 DSO for IgM and IgA). Anti-MPXV nAb were detectable in samples collected as early as 1 week after symptoms, with stable levels up to 20 DSO. After 2 weeks, IgG and nAb reached high titers. No significant differences were observed regardless of status of smallpox vaccination, human immunodeficiency virus positivity, or disease severity. Significant lower levels of IgM and IgG were observed in the patients treated with antivirals. These results contribute to extending the knowledge of the MPXV infection and the antibody response in a population with no historic smallpox vaccination., (© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

50. Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox.

Author

Mazzotta V, Cozzi-Lepri A, Lanini S, Mondi A, Carletti F, Tavelli A, Gagliardini R, Vita S, Pinnetti C, Aguglia C, Colavita F, Faccendini P, Matusali G, Faraglia F, Beccacece A, Paulicelli J, Girardi E, Nicastri E, Vaia F, Maggi F, and Antinori A

Subjects
Humans, Benzamides, Hospitalization, Isoindoles, Mpox (monkeypox)
Abstract

Tecovirimat is a treatment option for severe mpox, although randomized clinical trials are ongoing. The aim of the study is to assess the effect of tecovirimat on healing time and the extent of viral clearance by target trial emulation using observational data. Clinical and virological data of patients hospitalized for mpox were collected. Samples from the upper respiratory tract (URT) were grouped in two time points: T1 (median 6 days from symptoms onset) and T2 (median 5 days from T1). Patients were followed-up until recovery. Average treatment effect (ATE) in patients untreated versus treated with tecovirimat was estimated on time to healing and variation in viral load in URT, using a weighted and cloning analysis. Among the 41 patients included, 19 completed a course of tecovirimat. The median time from symptoms onset to hospitalization and to drug-starting was 4 days and 10 days, respectively. No improvement in healing time in treated versus untreated was observed. No difference by treatment group in time to viral clearance was detected by ATE fitted in a subset of 13 patients after controlling for confounders. We found no evidence for a large effect of tecovirimat in shortening healing time and viral clearance. While awaiting the results of randomized studies, the use of tecovirimat should be restricted to the clinical trial setting., (© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results